M Hvoslef-Eide1,2, A C Mar3,4,5, S R O Nilsson3,4, J Alsiö3,4,6, C J Heath3,4, L M Saksida3,4, T W Robbins3,4, T J Bussey3,4. 1. Department of Psychology, University of Cambridge, Downing Street, Cambridge, CB2 3EB, UK. mh473@cam.ac.uk. 2. MRC and Wellcome Trust Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, CB2 3EB, UK. mh473@cam.ac.uk. 3. Department of Psychology, University of Cambridge, Downing Street, Cambridge, CB2 3EB, UK. 4. MRC and Wellcome Trust Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, CB2 3EB, UK. 5. Department of Neuroscience and Physiology, New York University Medical Center, New York, NY, 10016, USA. 6. Department of Neuroscience, Unit of Functional Neurobiology, University of Uppsala, 75124, Uppsala, Sweden.
Abstract
RATIONALE: The NEWMEDS initiative (Novel Methods leading to New Medications in Depression and Schizophrenia, http://www.newmeds-europe.com ) is a large industrial-academic collaborative project aimed at developing new methods for drug discovery for schizophrenia. As part of this project, Work package 2 (WP02) has developed and validated a comprehensive battery of novel touchscreen tasks for rats and mice for assessing cognitive domains relevant to schizophrenia. OBJECTIVES: This article provides a review of the touchscreen battery of tasks for rats and mice for assessing cognitive domains relevant to schizophrenia and highlights validation data presented in several primary articles in this issue and elsewhere. METHODS: The battery consists of the five-choice serial reaction time task and a novel rodent continuous performance task for measuring attention, a three-stimulus visual reversal and the serial visual reversal task for measuring cognitive flexibility, novel non-matching to sample-based tasks for measuring spatial working memory and paired-associates learning for measuring long-term memory. RESULTS: The rodent (i.e. both rats and mice) touchscreen operant chamber and battery has high translational value across species due to its emphasis on construct as well as face validity. In addition, it offers cognitive profiling of models of diseases with cognitive symptoms (not limited to schizophrenia) through a battery approach, whereby multiple cognitive constructs can be measured using the same apparatus, enabling comparisons of performance across tasks. CONCLUSION: This battery of tests constitutes an extensive tool package for both model characterisation and pre-clinical drug discovery.
RATIONALE: The NEWMEDS initiative (Novel Methods leading to New Medications in Depression and Schizophrenia, http://www.newmeds-europe.com ) is a large industrial-academic collaborative project aimed at developing new methods for drug discovery for schizophrenia. As part of this project, Work package 2 (WP02) has developed and validated a comprehensive battery of novel touchscreen tasks for rats and mice for assessing cognitive domains relevant to schizophrenia. OBJECTIVES: This article provides a review of the touchscreen battery of tasks for rats and mice for assessing cognitive domains relevant to schizophrenia and highlights validation data presented in several primary articles in this issue and elsewhere. METHODS: The battery consists of the five-choice serial reaction time task and a novel rodent continuous performance task for measuring attention, a three-stimulus visual reversal and the serial visual reversal task for measuring cognitive flexibility, novel non-matching to sample-based tasks for measuring spatial working memory and paired-associates learning for measuring long-term memory. RESULTS: The rodent (i.e. both rats and mice) touchscreen operant chamber and battery has high translational value across species due to its emphasis on construct as well as face validity. In addition, it offers cognitive profiling of models of diseases with cognitive symptoms (not limited to schizophrenia) through a battery approach, whereby multiple cognitive constructs can be measured using the same apparatus, enabling comparisons of performance across tasks. CONCLUSION: This battery of tests constitutes an extensive tool package for both model characterisation and pre-clinical drug discovery.
Entities:
Keywords:
Attention; Cognitive flexibility; Drug discovery; Executive function; Long-term memory; Mouse; Neuropsychiatric disease; Rat; Response inhibition; Working memory
Authors: Gregory B Bissonette; Gabriela J Martins; Theresa M Franz; Elizabeth S Harper; Geoffrey Schoenbaum; Elizabeth M Powell Journal: J Neurosci Date: 2008-10-29 Impact factor: 6.167
Authors: K H Nuechterlein; M E Dawson; M Gitlin; J Ventura; M J Goldstein; K S Snyder; C M Yee; J Mintz Journal: Schizophr Bull Date: 1992 Impact factor: 9.306
Authors: Michael F Green; Pamela D Butler; Yue Chen; Mark A Geyer; Steven Silverstein; Jonathan K Wynn; Jong H Yoon; Vance Zemon Journal: Schizophr Bull Date: 2008-11-20 Impact factor: 9.306
Authors: Daniel J Calderone; Antígona Martinez; Vance Zemon; Matthew J Hoptman; George Hu; Jade E Watkins; Daniel C Javitt; Pamela D Butler Journal: Neuroimage Date: 2012-11-27 Impact factor: 6.556
Authors: Timothy P Rutkowski; Jason P Schroeder; Georgette M Gafford; Stephen T Warren; David Weinshenker; Tamara Caspary; Jennifer G Mulle Journal: J Neurosci Res Date: 2016-11-08 Impact factor: 4.164
Authors: Ian R Winship; Serdar M Dursun; Glen B Baker; Priscila A Balista; Ludmyla Kandratavicius; Joao Paulo Maia-de-Oliveira; Jaime Hallak; John G Howland Journal: Can J Psychiatry Date: 2018-05-09 Impact factor: 4.356
Authors: C A Oomen; M Hvoslef-Eide; D Kofink; F Preusser; A C Mar; L M Saksida; T J Bussey Journal: Psychopharmacology (Berl) Date: 2015-07-30 Impact factor: 4.530
Authors: Simon Ro Nilsson; Kim Fejgin; Francois Gastambide; Miriam A Vogt; Brianne A Kent; Vibeke Nielsen; Jacob Nielsen; Peter Gass; Trevor W Robbins; Lisa M Saksida; Tine B Stensbøl; Mark D Tricklebank; Michael Didriksen; Timothy J Bussey Journal: Cereb Cortex Date: 2016-08-09 Impact factor: 5.357